JF
RVNC

Jump Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Jump Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,122
Closed -$208K – 2351
2023
Q3 		$208K Sell
18,122
-110,945
-86% -$2.13M 0.01% 1499
2023
Q2 		$3.27M Buy
+129,067
New +$4.02M 0.12% 221
2023
Q1 		– Sell
-62,903
Closed -$1.16M – 2139
2022
Q4 		$1.16M Sell
62,903
-5,297
-8% -$121K 0.06% 409
2022
Q3 		$1.84M Sell
68,200
-1,642
-2% -$33.3K 0.07% 406
2022
Q2 		$966K Buy
+69,842
New +$1.08M 0.04% 592
2020
Q4 		– Sell
-18,365
Closed -$462K – 1223
2020
Q3 		$462K Buy
+18,365
New +$482K 0.09% 352

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jump Financial's RVNC Position: Q4 2023 in Review

Jump Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 18,122 shares — an estimated $208K sold.

Jump Financial first reported a position in RVNC in Q3 2020 and held it in 6 quarters. The position peaked at $3.27M in Q2 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Jump Financial reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Jump Financial sold 18,122 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $208K.
  • Jump Financial first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 6 quarters.
  • Jump Financial's Revance Therapeutics, Inc. position peaked at $3.27M in Q2 2023.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Jump Financial's 13F filing for Q4 2023, filed 7 Feb 2024.